Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LLH
|
|||
| Drug Name |
Penciclovir
|
|||
| Synonyms |
penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Recurrent herpes labialis [ICD-11: 1F00.01; ICD-10: B00.8] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Investigative | [2], [3] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H15N5O3
|
|||
| Canonical SMILES |
C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
|
|||
| InChI |
1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
|
|||
| InChIKey |
JNTOCHDNEULJHD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 39809-25-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9621, 626312, 5433020, 7784770, 7889775, 7980269, 8152897, 12013576, 14774399, 15122289, 26719824, 26758052, 26759330, 29223811, 46386598, 46504797, 46506498, 47207082, 49681570, 50028164, 53800602, 57322416, 58107003, 76356225, 85246619, 91615544, 92308296, 92309147, 92710506, 103158227, 103567639, 104307247, 118046008, 118314778, 124658988, 124799997, 125349760, 126631814, 126658134, 126664331, 128301646, 131313494, 134213303, 134222457, 134337781, 135030805, 135260574, 137005929, 137035478, 141089745
|
|||
| ChEBI ID |
CHEBI:7956
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | |||
| REF 3 | Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.